Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Cutaneous angiosarcoma (CAS) is a rare, malignant tumor of vascular mesenchymal origin accounting for less than 1% of all sarcomas.
To examine epidemiologic trends and outcomes in CAS.
In this retrospective, population-based study, patients with CAS were identified from the Surveillance Epidemiology and End Results database. Age, sex, and race-standardized incidence rates (IRs) were calculated. Survival was assessed with Kaplan-Meier curves and Cox proportional hazards models.
Of 811 patients with CAS, 43% had a prior primary cancer. CAS IR for patients without prior primary cancers dropped from 5.88 per 100,000 in 1973 to 1984 to 2.87 per 100,000 in 2005 to 2014. In those with prior primary cancers, IR rose from 0.03 per 100,000 in 1973 to 1984 to 2.25 per 100,000 in 2005 to 2014. On multivariate analysis, patients older than 70 years of age had a higher risk of death compared with those younger than 50 years (hazard ratio, 2.16; 95% confidence interval 1.33-3.57; P = .002), and distant disease was associated with increased risk of death compared with localized disease (hazard ratio, 1.50; 95% confidence interval, 1.11-2.03; P = .008). Receipt of surgery and/or radiation therapy was not associated with survival.
Potential selection and miscoding bias, retrospective nature.
CAS rates are rising among those with other prior primary cancers. Survival is not affected by current therapeutic strategies, highlighting the need for additional treatment options.Le texte complet de cet article est disponible en PDF.
Key words : angiosarcoma, cutaneous, disease-specific survival, incidence, outcomes, SEER
Abbreviations used : CAS, CI, IR, RT, SEER
| Funding sources: Dr Conic is supported by National Institute of Arthritis and Musculoskeletal and Skin Diseases grant 5 T32 AR 7569-23.
| Conflicts of interest: None disclosed.
| Reprints not available from the authors.